Anyone out there in this Study???
Posted: Fri Mar 05, 2004 6:14 pm
Hi All... Here is some info for you. I guess I am the controlled Study. I am about to enter the ACT Clinical Trial Study.
It is a two year double blind placebo study. Everyone gets Avonex,[which I am already on] and everyone gets a pill, [some placebo, some methotrexate] and one arm of the study will get pulse steroids at 2 month intervals.
I hope by the time I am done with this Antegren will be on the market.....or I will pull out early for it!!
I am worried...don't really know why......I've never been involved in a study before. Don't really know what to expect. I go to the MS Treatment Center Wednesday for a 4 hour workup..MRI...Blood...edss...wish me luck....kim
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH: [advanced]
Author:
Keyword(s):
Year: Vol: Page:
--------------------------------------------------------------------------------
Figures Only for this Article
Full Text of this Article
Reprint (PDF) Version of this Article
Citation Map
Email this article to a friend
Correspondence:
Submit a response to this article
Similar articles found in:
Neurology Online
PubMed
PubMed Citation
This Article has been cited by:
other online articles
Search PubMed for articles by:
Calabresi, P. A. || Whartenby, K. A.
Alert me when:
new articles cite this article
Download to Citation Manager
Collections under which this article appears:
Clinical trials Observational study (Cohort, Case control)
Multiple sclerosis
Neurology 2002;58:314-317
© 2002 American Academy of Neurology
--------------------------------------------------------------------------------
Brief Communications
An open-label trial of combination therapy with interferon ß-1a and oral methotrexate in MS
P. A. Calabresi, MD, J. L. Wilterdink, MD, J. M. Rogg, MD, P. Mills, RN, A. Webb and K. A. Whartenby, PhD
From the Department of Neurology (Dr. Calabresi), University of Maryland School of Medicine, Baltimore; and Departments of Clinical Neurosciences (Drs. Calabresi, Wilterdink, and Whartenby, and P. Mills and A. Webb) and Radiology (Dr. Rogg), Brown University School of Medicine, Providence, RI.
Address correspondence and reprint requests to Dr. P.A. Calabresi, Department of Neurology, University of Maryland School of Medicine, 655 W. Baltimore Street, Room 12-027, Baltimore, MD 21201; e-mail: pcala001@umaryland.edu
An open-label study was performed to evaluate the safety and efficacy of combination therapy with weekly oral methotrexate (20 mg) and interferon ß-1a (IFNß-1a) in 15 patients with MS who had experienced exacerbations while receiving IFNß monotherapy. Nausea was the only major side effect. A 44% reduction in the number of gadolinium-enhanced lesions seen on MRI scan was observed during combination therapy (p = 0.02). There was a trend toward fewer exacerbations. This combination therapy appears to be safe and well tolerated, and should be studied in a controlled trial.
This article has been cited by other articles:
P. A. Calabresi
Considerations in the treatment of relapsing-remitting multiple sclerosis
Neurology, April 23, 2002; 58(90084): S10 - 22.
[Abstract] [Full Text]
--------------------------------------------------------------------------------
It is a two year double blind placebo study. Everyone gets Avonex,[which I am already on] and everyone gets a pill, [some placebo, some methotrexate] and one arm of the study will get pulse steroids at 2 month intervals.
I hope by the time I am done with this Antegren will be on the market.....or I will pull out early for it!!
I am worried...don't really know why......I've never been involved in a study before. Don't really know what to expect. I go to the MS Treatment Center Wednesday for a 4 hour workup..MRI...Blood...edss...wish me luck....kim
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH: [advanced]
Author:
Keyword(s):
Year: Vol: Page:
--------------------------------------------------------------------------------
Figures Only for this Article
Full Text of this Article
Reprint (PDF) Version of this Article
Citation Map
Email this article to a friend
Correspondence:
Submit a response to this article
Similar articles found in:
Neurology Online
PubMed
PubMed Citation
This Article has been cited by:
other online articles
Search PubMed for articles by:
Calabresi, P. A. || Whartenby, K. A.
Alert me when:
new articles cite this article
Download to Citation Manager
Collections under which this article appears:
Clinical trials Observational study (Cohort, Case control)
Multiple sclerosis
Neurology 2002;58:314-317
© 2002 American Academy of Neurology
--------------------------------------------------------------------------------
Brief Communications
An open-label trial of combination therapy with interferon ß-1a and oral methotrexate in MS
P. A. Calabresi, MD, J. L. Wilterdink, MD, J. M. Rogg, MD, P. Mills, RN, A. Webb and K. A. Whartenby, PhD
From the Department of Neurology (Dr. Calabresi), University of Maryland School of Medicine, Baltimore; and Departments of Clinical Neurosciences (Drs. Calabresi, Wilterdink, and Whartenby, and P. Mills and A. Webb) and Radiology (Dr. Rogg), Brown University School of Medicine, Providence, RI.
Address correspondence and reprint requests to Dr. P.A. Calabresi, Department of Neurology, University of Maryland School of Medicine, 655 W. Baltimore Street, Room 12-027, Baltimore, MD 21201; e-mail: pcala001@umaryland.edu
An open-label study was performed to evaluate the safety and efficacy of combination therapy with weekly oral methotrexate (20 mg) and interferon ß-1a (IFNß-1a) in 15 patients with MS who had experienced exacerbations while receiving IFNß monotherapy. Nausea was the only major side effect. A 44% reduction in the number of gadolinium-enhanced lesions seen on MRI scan was observed during combination therapy (p = 0.02). There was a trend toward fewer exacerbations. This combination therapy appears to be safe and well tolerated, and should be studied in a controlled trial.
This article has been cited by other articles:
P. A. Calabresi
Considerations in the treatment of relapsing-remitting multiple sclerosis
Neurology, April 23, 2002; 58(90084): S10 - 22.
[Abstract] [Full Text]
--------------------------------------------------------------------------------